Molecular Partners AG
MOLN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001745114
No open-market purchases or sales by Molecular Partners AG insiders were filed in the last 90 days; 5 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Molecular Partners AG changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 8 | 8 | 0 |
| Shares | 1.35M | 878.8K | −475.8K (−35.1%) |
| Value | $27.6M | $5.93M | −$21.6M (−78.5%) |
New holders (3)
Institutions that held Molecular Partners AG at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citigroup Inc | 6,000 | $40.0K | 0.00% |
| High Net Worth Advisory Group LLC | 1,000 | $7.00K | 0.00% |
| Credit Suisse AG | 865 | $6.00K | 0.00% |
Sold out (3)
Institutions that held Molecular Partners AG at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Federated Hermes, Inc. | 457,037 | $9.26M |
| Millennium Management LLC | 23,942 | $485.0K |
| UBS Group AG | 611 | $12.0K |